The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, will struggle to meet its revenue goal.

Hims & Hers Health Inc.’s shares rose Tuesday after it said it was broadening its weight-loss offerings, adding access to brand name shots like Zepbound after previously focusing on cheaper versions ...

HIMS), recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound, Eli Lilly’s (NYSE: LLY) blockbuster weight loss drug. Zepbound is the most ...

Hims & Hers Health HIMS, recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound, Eli Lilly’s LLY blockbuster weight loss drug. Zepbound is ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.

In a short but sweet press release, Eli Lilly greatly diminished the enthusiasm that Zepbound would drive growth for Hims. It stated simply that “Eli Lilly and Company (NYSE:LLY) has no ...